sameAs
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersAnalysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesGermline mutations in BAP1 predispose to melanocytic tumorsVariants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphomaUnique de novo mutation of BRCA2 in a woman with early onset breast cancerFrequency of CHEK2*1100delC in New York breast cancer cases and controlsNo major association between TGFBR1*6A and prostate cancerA combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskA germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsGenome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaNetwork modeling links breast cancer susceptibility and centrosome dysfunctionGenetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypesSusceptibility loci associated with specific and shared subtypes of lymphoid malignanciesGenome-wide association study identifies multiple risk loci for chronic lymphocytic leukemiaIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized MedicineAnalysis of genetic variation in Ashkenazi Jews by high density SNP genotyping.Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies.Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.Genetic analysis of the early natural history of epithelial ovarian carcinomaEvaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersCommon genetic variants and modification of penetrance of BRCA2-associated breast cancerThe contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.Two decades after BRCA: setting paradigms in personalized cancer care and preventionBlood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.Counselling framework for moderate-penetrance cancer-susceptibility mutations.The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop.The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriersRisk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
P50
Q21144874-C4864C46-5978-47E3-9133-5CA77478F71DQ24170413-143FBEF5-1B8C-4B3E-9EEC-EF1D5D71BD04Q24594891-765163BB-7E19-446F-9F43-99F7C4D1D53AQ24632704-0F34BA82-4D5A-4DAA-9C50-A0B25F17F227Q24679634-8CBA87B8-D08B-407F-9850-72102F7FC91FQ24798279-115B86ED-77A6-4163-AECD-BDD171FF6B8DQ24798887-AEE8FAD5-E254-403D-83A6-204E25628BF5Q24803679-8E26AB67-8952-42B6-A0AE-0B36B4CCEF64Q27008356-FF7A8837-174A-490C-A1BB-520B5B67B09FQ27851467-933A415B-FA26-4FE2-8706-8C43D8883848Q28248768-694E1736-2399-47F0-B7CC-302D75ACD417Q28252491-E007F800-630E-4BE1-AE17-46E3E7556C5DQ28393571-98698C82-2CC1-4457-8DA0-2A8FE0ACBB40Q28943260-DE1BB63A-B509-4501-B888-EAD20CADF58AQ28943339-2955BCC0-360B-4D14-9108-EEF2D09BAD54Q30252854-A35378EA-6901-4A24-A4CE-198039E8435BQ30374367-B4318293-57E0-43AC-B91B-D97D86E7031BQ30513982-257D2BE4-E09E-472F-BD2D-FA57B96D4055Q30840823-275EE4A3-B238-409C-B278-F2A7DAAD4B79Q30992909-4BA504F0-3D71-4CCD-AFF8-3227E72BFD91Q31043651-8246CE49-B8B5-40BF-8734-D8A9000CECE6Q31082788-48336ABA-8655-4CFD-A947-CE5894A3780DQ33289120-AB4F0FE9-260F-40AC-BF2B-21C6C944FE6AQ33301585-967A1901-1138-46C3-A89E-463FF22C9208Q33423823-E2FA0EF3-D683-40B5-A8F8-78B7F0833E49Q33570452-CF51FDBB-ADC4-43E4-8C37-706A3D82B420Q33614244-90FDB341-BFCF-49A3-92AC-CCC8D2AB33F5Q33614244-E917E432-CF80-4608-9C00-DD177ED35337Q33742096-27002CF9-8D47-46F6-ACB7-0BDC637270ADQ33784408-BBD145CF-A6D5-4872-9F65-5A5B038900A5Q33817011-1DD6B897-C779-4E28-BA4C-1CF5F769362BQ33820594-CD2C17CF-2C2D-4B29-9165-9177AF13D2DBQ33833602-3C39F0B2-0263-4FB8-A692-D9E1796FD2BBQ33882519-159DEE7B-FD31-4991-B73B-8350CE459BAEQ33911135-12A352EA-BFE2-4925-8170-EDFFD9D4A9D5Q33946674-0983405C-211C-466D-94F2-6F6B14C15EE5Q34064381-AB1FBADC-ABA9-4608-B44E-53B4B55C5559Q34081324-F1E7290B-9954-4DD2-8A9A-87C1AB2BD5A9Q34113976-8724087E-56FE-4CC8-A0F6-462A3BA0CA70Q34115636-1F1A46B5-6EF5-4EEA-9FEF-9DC80962035F
P50
description
American cancer geneticist and oncologist
@en
geneticus
@nl
investigador
@es
name
Kenneth Offit
@ast
Kenneth Offit
@en
Kenneth Offit
@es
Kenneth Offit
@ga
Kenneth Offit
@nl
type
label
Kenneth Offit
@ast
Kenneth Offit
@en
Kenneth Offit
@es
Kenneth Offit
@ga
Kenneth Offit
@nl
prefLabel
Kenneth Offit
@ast
Kenneth Offit
@en
Kenneth Offit
@es
Kenneth Offit
@ga
Kenneth Offit
@nl
P1006
P214
P244
P269
P1006
P21
P213
0000 0001 1752 8598
P214
P244
P269
P31
P496
0000-0002-7454-329X
P569
1955-02-19T00:00:00Z
P735
P7859
lccn-n97801730